On a Wednesday, the reversal occurred. On a Tuesday, the story had been published. In the middle, perhaps in a Detroit office building or during a conference call that no one will ever discuss in public, Blue Cross Blue Shield of Michigan came to the conclusion that it could, in fact, pay for the kidney transplant that it had previously declined to cover at Michigan Medicine. It’s difficult to ignore the timeline’s math. Paperwork, phone calls, months of waiting, and a certain kind of tiredness that only sick people and their families can relate to. Next, an article in the newspaper. Abruptly, a yes.
The speed is what persists. Not the approval itself, which was the only humane solution and the correct one, but the fact that the equipment needed to produce it had apparently been there all along. The power to flip the switch belonged to someone, somewhere. They simply hadn’t until the story appeared in the Detroit Free Press on May 5. The denial, which had been explained away as a matter of contract technicalities and service dates, quietly vanished in about twenty-four hours.
Here, the background is important. If a new agreement isn’t reached by June 30, Blue Cross and Michigan Medicine, the academic medical system affiliated with the University of Michigan in Ann Arbor, could force up to 300,000 patients out of the network on July 1. That’s the kind of figure that seems abstract until you realize that it represents people, such as cancer patients, transplant candidates, children undergoing lengthy treatment regimens, and expectant mothers midway through a high-risk pregnancy. One of them is the kidney patient. It just so happened that a reporter wrote about him.
Observing an insurer move at the speed of negative publicity when it doesn’t seem to be able to move at the speed of a failing organ is unsettling. Individuals on transplant waiting lists are aware of how time functions within their own bodies. Negotiations don’t stop kidney function. The clinical literature is indifferent to this; as waiting time increases, postoperative outcomes, dialysis dependence, and mortality rates all worsen. Over 300 people in the UK passed away last year while awaiting a kidney, or about six every week. Contract memos don’t contain numbers like that.
Comments on the Free Press’s Instagram post about the reversal accumulated in a tone that was half resignation and half indignation. According to one reader, the transplant was only approved because the company was forced to do so by the paper. Another, who had been a Blue Cross customer for fifteen years, declared she was done. The responses read less like grievances and more like a modest public reckoning, the kind that gradually intensifies before ceasing.
It’s difficult to ignore how frequently these tales have the same structure. A denial that defies logic. A family unable to receive a clear response. At last, a journalist makes a call. And then the reversal, which happened almost embarrassingly quickly. The pattern has become so well-known that it is now discussed as a tactic on social media: get a reporter. The official appeals process, which insurance companies promote as impartial and comprehensive, is perceived as being slower and less responsive than a single phone call from a newsroom.
Blue Cross will correctly point out that a system is not defined by a single approval. Michigan Medicine will claim that it is still fighting for its patients. The contract clock will continue to run until June 30. A man in Ann Arbor is getting ready for surgery that he was informed he couldn’t have covered not too long ago. His timeline shrank from several months to just one news cycle. You can’t help but wonder how many other patients are still waiting for their story to be published.
